[18F]fluorodeoxyglucose (FDG) positron emission tomography (PET)/computed tomography (CT) has been reported to have a low sensitivity in the initial diagnosis of bronchoalveolar carcinoma (BAC) due to BAC's low metabolic activity. The aim of this study was to assess the value of [18F]FDG‑PET/CT in the detection of BAC recurrence. Between February 2007 and September 2011, the [18F]FDG‑PET/CT scans that were performed on patients with known, histologically proven BAC were studied. A total of 24 [18F]FDG‑PET/CT scans were performed in 22 patients, including 16 males and 6 females, with a mean age of 65±9 years. Among the scans, 15 were performed to assess for possible recurrence with equivocal findings in conventional imaging methods and 9 for restaging post‑therapy. In all cases conventional imaging studies (CT and MRI) were performed 5‑30 days prior to PET/CT. Among the 24 [18F]FDG‑PET/CT scans, 18 were positive and 6 negative. Among the 15 [18F]FDG‑PET/CT scans performed for suspected recurrence, 34 lesions were detected and the mean maximum standardized uptake value (SUVmax) was 6.8±3.26. In nine scans, upstaging was observed, while two were in agreement with the findings of the conventional modalities. A greater number of lesions were detected in two scans and fewer lesions were detected in one, with no change in staging. Only one scan was negative. By contrast, in patients examined for restaging, there were only five lesions with a mean SUVmax of 4.86±3.18. Agreement between the findings of [18F]FDG‑PET/CT and the conventional modalities was observed in 8 out of 9 cases. Although [18F]FDG‑PET/CT has been reported to have a low sensitivity in the initial diagnosis of BAC, the present results indicate that when there is recurrence, the lesions become [18F]FDG avid. [18F]FDG‑PET/CT may provide further information in patients evaluated for recurrence and thus improve patient management.

Related Articles